THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related disease…Original Article
Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease
